Ruhi Khan

Route 53 Outlook Zendesk Amazon AWS UptimeRobot Adobe Marketing Cloud Mobile Friendly Akamai RUM reCAPTCHA Greenhouse.io New Relic Apache Google Tag Manager Vimeo Remote

nextgeneration crispr genome editing allogeneic cart cell therapies oncology autoimmune biotechnology agriculture synthetic biology life sciences biotechnology: biological products (no diagnostic substances) health care biotechnology research crispr genome editing car-t cell therapy allogeneic therapies off-the-shelf therapies chrdna technology checkpoint disruption immune cloaking pd-1 knockout gene knockout multiplex gene editing targeted therapies hematologic malignancies autoimmune diseases b cell non-hodgkin lymphoma multiple myeloma acute myeloid leukemia t cell expansion cas12a technology clinical trials drug development biopharmaceuticals genomic integrity tcr knockout b2m knockout hla class i expression functional genomics therapeutic efficiency cellular therapies genome engineering armored car-t cells healthcare innovation biotech partnerships patient access fda designations investigational therapies treatment personalization chimeric antigen receptor crispr-edited therapies treatment efficacy therapeutic pipelines regenerative medicine therapeutic discovery biomedical research advanced therapy medicinal products crispr technology allogeneic cell therapies precision medicine transformative therapies patient outcomes innovative solutions healthcare providers biotechnology researchers pharmaceutical companies patient advocacy groups clinical-stage candidates immune checkpoint disruption proprietary technology chrdna fda fast track designation collaborative partnerships cancer treatment genetic diseases therapeutic development biotherapeutics gene therapy immuno-oncology cell therapy market hospital & health care health wellness & fitness